A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must have:
Asymptomatic or minimally symptomatic HIV infection (no evidence of AIDS).
CD4 count <= 400 cells/mm3 within 6 weeks prior to study entry (CD4 count changed to 100 - 400 cells/mm3 per amendment).
Tolerated the current nucleoside analog antiretroviral treatment for at least 4 weeks prior to study entry.
Patients with the following symptoms or conditions are excluded:
Known hypersensitivity to thymopentin or any component of the formulation.
Significant chronic underlying medical illness that would impede study participation.
Grade 2 or higher peripheral neuropathy related to nucleoside analog antiretroviral treatment.
Any antiretroviral agents other than zidovudine, didanosine, or dideoxycytidine.
HIV vaccines or any investigational or non-FDA approved medication or immunomodulatory or experimental therapy within 30 days prior to study entry.
Patients with the following prior condition are excluded:
Abnormal chest x-ray consistent with active opportunistic infection within 6 weeks prior to study entry.
Any prior antiretroviral agents other than zidovudine, didanosine, or dideoxycytidine within 30 days prior to study entry.
Current nucleoside analog antiretroviral treatment.
Nucleoside analog antiretroviral treatment for at least 4 weeks prior to study entry.
Significant active alcohol or drug abuse sufficient to prevent study compliance.